iShares MSCI Singapore ETF vs 22nd Century Group Inc — how do they compare? iShares MSCI Singapore ETF trades at $31.78, while 22nd Century Group Inc trades at $4.33 (market cap $1.52M). Which is the better fit depends on your goals.
| EWS | XXII | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $32.09 | $1.47K |
52-Week Low | $26.47 | $3.90 |
Market Cap | — | $1.52M |
Enterprise Value | — | -$6.71M |
Signals from Pluang's Aura AI — not financial advice
EWS trades at $31.825, up 0.62% with strong technical momentum as moving averages signal bullish alignment. The ETF benefits from Singapore's economic resilience and AI-driven growth narrative, though key financial ratios remain undisclosed. Recent news highlights Singapore's strategic positioning in Asian markets and financial sector strength, with a dividend of $0.52 scheduled for June 2026.
Outlook remains positive given technical strength and regional economic tailwinds, but overbought RSI readings suggest near-term consolidation risk. The concentrated financials exposure (54% of holdings) ties performance to banking sector stability, while AI infrastructure investments offer growth catalysts. Investors should monitor Singapore's economic policies and global market volatility.
22nd Century Group (XXII) trades at $4.33, up 3.34% on the day, following a recent 20:1 reverse stock split. The stock shows a bearish technical signal with support at $4 and resistance at $5. Fundamentally, the company continues to operate at a loss with negative gross and net profit margins, though revenue reached $7.05M in 2025. Recent news highlights aggressive expansion of its VLN reduced-nicotine cigarette brand into California and New York markets.
The outlook remains speculative with significant execution risk. While analyst consensus is strongly bullish (75% buy ratings), the company must demonstrate a path to profitability through its VLN product expansion. Key risks include persistent cash burn, competitive tobacco market pressures, and regulatory uncertainty. The stock represents a high-risk, high-potential turnaround play dependent on commercial success of its reduced-nicotine platform.
Trailing returns across standard periods
Latest headlines on both assets
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →